According to the Zhitong Finance App, Kehua Biotech (002022.SZ) released a performance forecast. Net profit to the mother in 2023 is expected to lose, mainly due to a sharp drop in market demand for related products.

Facing changes in domestic and foreign markets, in order to promote the company's sustainable and healthy development, the company has accumulated energy and increased investment in the following areas: (1) actively adjust the product strategy layout and continue to invest in new tracks and product upgrades and iterations: innovate and compete in the fields of human medicine, animals, and automation to develop new products; maintain integrity and innovation in various areas such as infectious diseases, tumors, genetic metabolism, drug genes, blood screening, etc., and continue to promote product upgrades and iterations to achieve comprehensive coverage of biochemical, immunoluminescence, molecular and mass spectrometry product lines; (2) continue to promote overall international solutions; (2) continue to promote overall international solutions; A strategy of transformation, Increase investment in overseas markets, establish sales and after-sales networks in many countries and regions; (3) optimize organizational structures, lean management, improve management efficiency, and fully tap the potential for improving quality and efficiency.

The company continues to deepen cooperation with leading international in vitro diagnostic companies, adhere to the development strategy of two-wheel drive instruments and reagents, continuously improve R&D innovation capabilities and industrial transformation capabilities, continuously optimize product costs, improve product quality, and enhance the company's core competitiveness, so as to enhance the company's ability to withstand market risks and explore global markets in the future.